4//SEC Filing
Farwell Wildon 4
Accession 0001209191-23-058328
CIK 0001818794other
Filed
Dec 11, 7:00 PM ET
Accepted
Dec 12, 5:33 PM ET
Size
7.8 KB
Accession
0001209191-23-058328
Insider Transaction Report
Form 4
Farwell Wildon
Chief Medical Officer
Transactions
- Sale
Common Stock
2023-12-11$10.72/sh−1,688$18,095→ 170,074 total - Sale
Common Stock
2023-12-12$10.55/sh−978$10,318→ 169,096 total
Footnotes (5)
- [F1]Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.72 to $10.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F3]Includes 145,667 unvested RSUs.
- [F4]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 14, 2023.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.37 to $10.75, inclusive.
Documents
Issuer
Dyne Therapeutics, Inc.
CIK 0001818794
Entity typeother
Related Parties
1- filerCIK 0001847941
Filing Metadata
- Form type
- 4
- Filed
- Dec 11, 7:00 PM ET
- Accepted
- Dec 12, 5:33 PM ET
- Size
- 7.8 KB